The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Diabetes, Obesity and Metabolism · 2024-07 · 26 (7) · 2706-2721
DOI: 10.1111/dom.15586 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 11.04.2024. Verfasst von Leonardo Buttice und 13 weiteren Autor:innen. Beteiligte Einrichtung: University College London (UCL), London, UK. Hauptthemen laut MEDLINE: Biomarkers, Diabetes Mellitus, Type 2, Inflammation, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
To conduct a meta‐analysis of randomized controlled trials (RCTs) to assess the effect of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors on inflammatory biomarkers.
Methods
Medline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity.
Results
Thirty‐eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow‐up of 16 (12–24) weeks. Meta‐analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin‐6, tumour necrosis factor receptor‐1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model assessment of insulin resistance index (vs. control: SMD −0.20 [95% CI −0.33, −0.07], MD −0.83 [95% CI −1.32, −0.33], respectively). There were no significant changes in C‐reactive protein (CRP), tumour necrosis factor‐α, plasminogen activator inhibitor‐1, fibroblast growth factor‐21 or monocyte chemoattractant protein‐1.
Conclusions
Our analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University College London (UCL), London, UK.
- Grange University Hospital, Cwmbran, UK.
- Institute of Life Sciences 2, Swansea Bay University Health Board and Swansea University Medical School, Swansea, UK.
- Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK.
- Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.
- Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
ORCID-Profile: Leonardo Buttice, James H P Gamble, Jeffrey W Stephens, Jonathan J H Bray
Zitieren
APA
Buttice, L., Ghani, M., Suthakar, J., Gnanalingham, S., Carande, E., Kennedy, B. W. C., Pitcher, A., Gamble, J. H. P., Ahmad, M., Lewis, A., Jüni, P., Rider, O. J., Stephens, J. W., & Bray, J. J. H. (2024). The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 26(7), 2706-2721. https://doi.org/10.1111/dom.15586
Vancouver
Buttice L, Ghani M, Suthakar J, Gnanalingham S, Carande E, Kennedy BWC, et al. The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2024;26(7):2706-2721. doi:10.1111/dom.15586
BibTeX
@article{Buttice2024,
author = {Buttice, Leonardo and Ghani, Maryam and Suthakar, Janahan and Gnanalingham, Sathyan and Carande, Elliott and Kennedy, Brett W C and Pitcher, Alex and Gamble, James H P and Ahmad, Mahmood and Lewis, Andrew and Jüni, Peter and Rider, Oliver J and Stephens, Jeffrey W and Bray, Jonathan J H},
title = {The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
volume = {26},
number = {7},
pages = {2706--2721},
doi = {10.1111/dom.15586}
}
EUVIMED